Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases.

Granata V, Fusco R, Maio F, Avallone A, Nasti G, Palaia R, Albino V, Grassi R, Izzo F, Petrillo A.

Infect Agent Cancer. 2019 Nov 27;14:40. doi: 10.1186/s13027-019-0264-3. eCollection 2019.

2.

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.

Ottaiano A, Scala S, Normanno N, Napolitano M, Capozzi M, Rachiglio AM, Roma C, Trotta AM, D'Alterio C, Portella L, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Tafuto S, Avallone A, De Stefano A, Tamburini M, Picone C, Petrillo A, Izzo F, Palaia R, Albino V, Amore A, Belli A, Pace U, Di Marzo M, Chiodini P, Botti G, De Feo G, Delrio P, Nasti G.

BMC Cancer. 2019 Sep 9;19(1):899. doi: 10.1186/s12885-019-6109-z.

3.

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.

Ottaiano A, Capozzi M, Tafuto S, De Stefano A, De Divitiis C, Romano C, Avallone A, Nasti G.

Front Oncol. 2019 Aug 13;9:766. doi: 10.3389/fonc.2019.00766. eCollection 2019.

4.

Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms.

von Arx C, Capozzi M, López-Jiménez E, Ottaiano A, Tatangelo F, Di Mauro A, Nasti G, Tornesello ML, Tafuto S.

J Clin Med. 2019 Aug 22;8(9). pii: E1277. doi: 10.3390/jcm8091277. Review.

5.

Metastatic Colorectal Cancer: Prognostic And Predictive Factors.

Nappi A, Nasti G, Romano C, Berretta M, Ottaiano A.

Curr Med Chem. 2019 Jun 20. doi: 10.2174/0929867326666190620110732. [Epub ahead of print]

PMID:
31218949
6.

Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study.

Lonardi S, Nasti G, Fagnani D, Gemma D, Ciuffreda L, Granetto C, Lucchesi S, Ballestrero A, Biglietto M, Proserpio I, Bergamo F, Proietti E, Tonini G.

Tumori. 2019 Jun;105(3):243-252. doi: 10.1177/0300891619834126. Epub 2019 Mar 11.

PMID:
30857495
7.

Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors.

Ottaiano A, Scotti V, De Divitiis C, Capozzi M, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Vicario V, De Stefano A, Tafuto S, Berretta M, Nasti G, Avallone A.

Oncotarget. 2018 Oct 16;9(81):35251-35265. doi: 10.18632/oncotarget.25834. eCollection 2018 Oct 16.

8.

Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples.

Capozzi M, De Divitiis C, Ottaiano A, Teresa T, Capuozzo M, Maiolino P, Botti G, Tafuto S, Avallone A; Abdominal Oncology Group.

Front Public Health. 2018 Oct 12;6:291. doi: 10.3389/fpubh.2018.00291. eCollection 2018.

9.

A radiologist's point of view in the presurgical and intraoperative setting of colorectal liver metastases.

Granata V, Fusco R, Avallone A, Catalano O, Piccirillo M, Palaia R, Nasti G, Petrillo A, Izzo F.

Future Oncol. 2018 Sep;14(21):2189-2206. doi: 10.2217/fon-2018-0080. Epub 2018 Aug 7. Review.

PMID:
30084273
10.

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.

Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A.

Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Review.

11.

Can the addition of radiotherapy postoperatively increase clinical outcome of patients with gastric cancer? A systematic review of the literature and meta-analysis.

Fiorica F, Trovò M, Ottaiano A, Nasti G, Carandina I, Marzola M, De Paoli P, Berretta M.

Oncotarget. 2017 Dec 28;9(12):10734-10744. doi: 10.18632/oncotarget.23754. eCollection 2018 Feb 13.

12.

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.

Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F.

PLoS One. 2018 Jan 19;13(1):e0191593. doi: 10.1371/journal.pone.0191593. eCollection 2018.

13.

Is It Possible a Conservative Approach After Radiochemotherapy in Locally Advanced Rectal Cancer (LARC)? A Systematic Review of the Literature and Meta-analysis.

Fiorica F, Trovò M, Anania G, Marcello D, Di Benedetto F, Marzola M, D'Acapito F, Nasti G, Berretta M.

J Gastrointest Cancer. 2019 Mar;50(1):98-108. doi: 10.1007/s12029-017-0041-8.

PMID:
29273921
14.

FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.

Ottaiano A, Nasti G, Cassata A, De Stefano A, Caraglia M, Avallone A.

Cancer Lett. 2017 Nov 1;408:71-72. doi: 10.1016/j.canlet.2017.08.025. Epub 2017 Aug 24. No abstract available.

PMID:
28844712
15.

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.

Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators.

Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20.

PMID:
28735067
16.

Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.

Ottaiano A, Capozzi M, DE Divitiis C, VON Arx C, DI Girolamo E, Nasti G, Cavalcanti E, Tatangelo F, Romano G, Avallone A, Tafuto S.

Anticancer Res. 2017 Apr;37(4):1975-1978.

PMID:
28373469
17.

Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment.

Barbieri A, Quagliariello V, Del Vecchio V, Falco M, Luciano A, Amruthraj NJ, Nasti G, Ottaiano A, Berretta M, Iaffaioli RV, Arra C.

Nutrients. 2017 Feb 28;9(3). pii: E210. doi: 10.3390/nu9030210.

18.

Serum and tissue markers in colorectal cancer: State of art.

Berretta M, Alessandrini L, De Divitiis C, Nasti G, Lleshi A, Di Francia R, Facchini G, Cavaliere C, Buonerba C, Canzonieri V.

Crit Rev Oncol Hematol. 2017 Mar;111:103-116. doi: 10.1016/j.critrevonc.2017.01.007. Epub 2017 Jan 27. Review.

PMID:
28259285
19.

Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey.

Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, Nasti G, Fisichella R, Romano C, De Divitiis C, Taibi R, Fiorica F, Di Francia R, Di Mari A, Del Pup L, Crispo A, De Paoli P, Santorelli A, Quagliariello V, Iaffaioli RV, Tirelli U, Facchini G.

Oncotarget. 2017 Apr 11;8(15):24401-24414. doi: 10.18632/oncotarget.14224.

20.

Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives.

Nappi A, Berretta M, Romano C, Tafuto S, Cassata A, Casaretti R, Silvestro L, Divitiis C, Alessandrini L, Fiorica F, Ottaiano A, Nasti G.

Curr Cancer Drug Targets. 2018;18(5):421-429. doi: 10.2174/1568009617666170209095143. Review.

PMID:
28183254

Supplemental Content

Loading ...
Support Center